Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Neoplasms 3Non-Small Cell Lung Cancer Metastatic 1Lung Neoplasms 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Deafness, Autosomal Recessive 39 1Colorectal Neoplasms 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Bevacizumab 233Fluorouracil 219Oxaliplatin 215Irinotecan 215Leucovorin 198Capecitabine 153Cetuximab 145Panitumumab 70Folfox protocol 51regorafenib 43Radiotherapy 38pembrolizumab 37IFL protocol 36HMPL-013 36trifluridine tipiracil drug combination 32Nivolumab 32Drug Therapy 26Neoadjuvant Therapy 24Trifluridine 18Celecoxib 18tislelizumab 17XELOX 17sintilimab 16Trastuzumab 16durvalumab 15atezolizumab 15aflibercept 15Chemotherapy, Adjuvant 15apatinib 14Gemcitabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Neoplasms × tepotinib × Clear all
NCT04515394 2022-12-22

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

EMD Serono

Phase 2 Terminated
3 enrolled 6 charts
Gastrointestinal

Deafness, Autosomal Recessive 39, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡